OHB Pediatrics Ltd. is preparing for a major transformation as it merges with Research Alliance Corp III, a move that will see the company rebranded as Oak Hill Bio Inc. This merger is significant not only for OHB but also for the pharmaceutical preparations sector, indicating a consolidation trend that could reshape the industry landscape.

The merger was officially announced in a recent SEC filing, detailing the Business Combination Agreement approved by the board of directors of Research Alliance Corp III on July 26, 2026. This strategic move is expected to enhance operational efficiencies and broaden the market reach of the newly formed entity.

Background

OHB Pediatrics Ltd., classified under the SIC code 2834 for Pharmaceutical Preparations, is a company incorporated in England and Wales. It has been involved in developing pediatric medicines aimed at improving health outcomes for children. The recent SEC filings indicate that OHB is categorized as a smaller reporting company and an emerging growth company.

Research Alliance Corp III, the merging partner, is a Cayman Islands exempted company that has been actively pursuing opportunities to enhance its portfolio in the life sciences sector. The company has been listed on the Nasdaq Capital Market under the ticker symbol RACC.

What the Filing Says

The SEC filing, dated November 4, 2026, outlines the merger details, including the conversion of shares and the transition of Research Alliance Corp III from a Cayman Islands entity to a Delaware corporation. According to the filing, "RACC will de-register from the Register of Companies in the Cayman Islands and transfer by way of continuation from the Cayman Islands to Delaware." This transition is part of the domestication process that will accompany the name change to Oak Hill Bio Inc.

Additionally, the filing mentions that RACC will acquire 100% of the issued shares in the capital of Oak Hill Bio from its shareholders in exchange for newly issued shares of common stock, valued at $10.00 per share. This transaction is expected to result in the issuance of approximately 9,098,529 shares of common stock of the new entity.

Impact

This merger will have significant implications for various stakeholders, including existing shareholders of both companies. Public shareholders of RACC will experience immediate dilution due to the share conversion and issuance of new shares. The filing notes that public shareholders who do not redeem their shares will receive one share of New OHB Common Stock for each RACC Class A Share held prior to the domestication.

The merger also highlights potential conflicts of interest, particularly concerning the Sponsor and RACC's officers and directors, as they will receive shares that may dilute the equity interests of non-redeeming public shareholders. The filing emphasizes the importance of transparency in these transactions to protect shareholder interests.

What's Next

The next steps involve holding an extraordinary general meeting where shareholders will vote on the proposed transactions. Approval requires a special resolution from the holders of RACC Class B Shares and an ordinary resolution from the holders of RACC Shares. The filing indicates that the approval of the merger is contingent upon meeting specific conditions, including Nasdaq listing requirements for the new shares.

As the merger progresses, stakeholders are encouraged to stay informed about the developments and implications of this significant transaction in the pharmaceutical preparations industry.